Company Description
Skye Bioscience, Inc., a clinical-stage biotechnology company, develops molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and related metabolic diseases.
The company's lead clinical asset is nimacimab, a peripherally-restricted negative allosteric modulating antibody targeting cannabinoid receptor 1 (CB1) administered as a subcutaneous injectable, which targets CB1 receptors in peripheral tissues including adipose, liver, and muscle tissues with limited central nervous system accumulation.
Nimacimab addresses metabolic processes related to energy expenditure, fat mobilization, leptin sensitivity, appetite regulation, and satiety signaling.
Skye Bioscience, Inc. was formerly known as Emerald Bioscience Inc. and changed its name to Skye Bioscience, Inc. in December 2020.
Skye Bioscience, Inc. was incorporated in 2011 and is based in San Diego, California.
| Country | United States |
| Founded | 2012 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 2 |
| CEO | Punit Dhillon |
Contact Details
Address: 11250 El Camino Real, Suite 100 San Diego, California 92130 United States | |
| Phone | 858 410 0266 |
| Website | skyebioscience.com |
Stock Details
| Ticker Symbol | SKYE |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 1516551 |
| CUSIP Number | 83086J309 |
| ISIN Number | US83086J3095 |
| Employer ID | 45-0692882 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Punit S. Dhillon B.A. | President, Chief Executive Officer and Director |
| John P. Sharp CPA | Chief Financial Officer and Principal Financial and Accounting Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 24, 2026 | SCHEDULE 13D/A | Filing |
| Sep 11, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Sep 11, 2026 | 8-K | Current Report |
| Aug 24, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Aug 24, 2026 | 8-K | Current Report |
| Aug 20, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Aug 20, 2026 | 8-K/A | [Amend] Current report |
| Aug 19, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Aug 19, 2026 | 8-K | Current Report |
| Aug 18, 2026 | SCHEDULE 13D/A | Filing |